I appreciate your interest in our study, and would like to share clinical experiences regarding the article titled “COVID-19: A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis,” in which the use of steroids was demonstrated to not be efficacious, albeit the underlying asthma [1]. COVID-19 can be defined as a hypersensitivity reaction by SARS-CoV-2 infection. Its exact pathophysiology may be unraveled in future through extensive scientific evidence. Its clinical manifestations are greatly diverse, and the immune system (including innate and adaptive immunity) seems to play a major role in clearing the virus. Many cells, such as monocytes, macrophages, eosinophils, neutrophils, and lymphocytes might contribute to the surge of cytokines that induce inflammation and cell death. Excessive inflammation can promote the extracellular spread of the virus and lead to lung destruction. We have suggested in our report that prednisolone (PD) could be important for treatment of this condition; based on the hypothesis that COVID-19 is a hypersensitivity pneumonitis (HP) [2].